|
DE2847693A1
(de)
*
|
1978-11-03 |
1980-05-22 |
Hoechst Ag |
Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
|
|
US4814335A
(en)
*
|
1982-12-30 |
1989-03-21 |
Biomeasure, Incorporated |
Antiviral compounds
|
|
US4625026A
(en)
*
|
1982-12-30 |
1986-11-25 |
Biomeasure, Inc. |
2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections
|
|
JPS6442472A
(en)
*
|
1987-08-10 |
1989-02-14 |
Kanebo Ltd |
Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
|
|
US4877790A
(en)
*
|
1987-12-15 |
1989-10-31 |
Kanebo Limited |
Quinazoline derivative, processes for its production, and cerebral dysfunction remedying agent comprising it as active ingredient
|
|
TW334434B
(en)
*
|
1995-05-16 |
1998-06-21 |
Kanebo Ltd |
Novel quinazoline compound and anti-tumor agent
|
|
AU2769897A
(en)
*
|
1996-05-07 |
1997-11-26 |
Basf Aktiengesellschaft |
Imidazoquinazolines, agents containing them and their use to combat fungi and animal pests
|
|
MXPA03005854A
(es)
*
|
2001-01-02 |
2003-09-10 |
Hoffmann La Roche |
Derivados de quinazolona como antagonistas del receptor adrenergico alfa 1a/b.
|
|
US6900220B2
(en)
|
2001-01-02 |
2005-05-31 |
Syntex (U.S.A.) Llc |
Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
|
|
CA2447132C
(en)
*
|
2001-05-14 |
2008-10-07 |
Omnova Solutions Inc. |
Polymeric surfactants derived from cyclic monomers having pendant fluorinated carbon groups
|
|
EP1398032A1
(en)
*
|
2002-09-10 |
2004-03-17 |
PheneX Pharmaceuticals AG |
4-Oxo-quinazolines as LXR nuclear receptor binding compounds
|
|
EP1407774A1
(en)
*
|
2002-09-10 |
2004-04-14 |
LION Bioscience AG |
2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
|
|
KR100735781B1
(ko)
|
2002-10-01 |
2007-07-06 |
미쯔비시 웰 파마 가부시키가이샤 |
이소퀴놀린 화합물 및 그의 의약 용도
|
|
US7501412B2
(en)
|
2002-11-22 |
2009-03-10 |
Mitsubishi Tanabe Pharma Corporation |
Isoquinoline compounds and medicinal use thereof
|
|
MXPA06005687A
(es)
|
2003-11-20 |
2006-08-17 |
Janssen Pharmaceutica Nv |
2-quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de la poli(adenosin fosfato-ribosa)polimerasa.
|
|
CA2546002C
(en)
|
2003-11-20 |
2012-09-18 |
Janssen Pharmaceutica N.V. |
7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
|
|
CA2569826C
(en)
|
2004-06-30 |
2013-07-16 |
Janssen Pharmaceutica N.V. |
Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
|
|
EA014955B1
(ru)
|
2004-06-30 |
2011-04-29 |
Янссен Фармацевтика Н. В. |
Производные фталазина в качестве ингибиторов parp
|
|
WO2006003148A1
(en)
|
2004-06-30 |
2006-01-12 |
Janssen Pharmaceutica N.V. |
Quinazolinedione derivatives as parp inhibitors
|
|
EP1854795B1
(en)
*
|
2005-02-18 |
2016-06-01 |
Mitsubishi Tanabe Pharma Corporation |
Salt of a proline derivative, solvate thereof, and production method thereof
|
|
RS51423B
(sr)
|
2006-03-31 |
2011-02-28 |
Janssen Pharmaceutica N.V. |
Benzoimidazol-2-il pirimidini i pirazini kao modulatori histaminskog h4 receptora
|
|
CA2678248C
(en)
|
2007-03-08 |
2016-06-28 |
Janssen Pharmaceutica Nv |
Quinolinone derivatives as parp and tank inhibitors
|
|
EP2215075B1
(en)
|
2007-10-26 |
2013-12-11 |
Janssen Pharmaceutica, N.V. |
Quinolinone derivatives as parp inhibitors
|
|
EP2260026B1
(en)
|
2008-03-27 |
2011-06-22 |
Janssen Pharmaceutica, N.V. |
Quinazolinone derivatives as tubulin polymerization inhibitors
|
|
SI2271626T1
(sl)
|
2008-03-27 |
2015-03-31 |
Janssen Pharmaceutica, N.V. |
Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina
|
|
US9371311B2
(en)
|
2008-06-30 |
2016-06-21 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-yl pyrimidine derivatives
|
|
TW201018668A
(en)
*
|
2008-06-30 |
2010-05-16 |
Janssen Pharmaceutica Nv |
Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
|
|
KR101805754B1
(ko)
|
2008-12-08 |
2017-12-07 |
먼디파머 인터내셔널 코포레이션 리미티드 |
단백질 수용체 티로신 키나아제 억제제의 조성물
|
|
EP2526099B1
(en)
*
|
2010-01-18 |
2016-03-30 |
MSN Laboratories Limited |
Improved process for the preparation of amide intermediates and their use thereof
|
|
WO2012131706A1
(en)
*
|
2011-03-20 |
2012-10-04 |
Cadila Healthcare Limited |
Amorphous form of vilazodone hydrochloride and process for its preparation
|
|
DE102011113749A1
(de)
*
|
2011-09-14 |
2013-03-14 |
Aicuris Gmbh & Co. Kg |
Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
|
|
CA2849779A1
(en)
*
|
2011-09-30 |
2013-04-04 |
Janssen Pharmaceutica Nv |
Crystalline hydrochloride salt of (1- (4 -fluorophenyl) - 1h - indol - 5 - yl) - (3- (4- (thiazole - 2 - carbonyl) piperazin-1 - yl) az etidin- 1 -yl) methanone and its use in the treatment of pain and metabolic disorders
|
|
WO2013138495A1
(en)
*
|
2012-03-15 |
2013-09-19 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
|
JP6317320B2
(ja)
|
2012-03-15 |
2018-04-25 |
セルジーン シーエーアール エルエルシー |
上皮成長因子受容体キナーゼ阻害剤の塩
|
|
US20130261134A1
(en)
*
|
2012-03-30 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Mesylate salt forms of a potent hcv inhibitor
|
|
AU2014214846A1
(en)
|
2013-02-08 |
2015-07-23 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
|
JO3516B1
(ar)
|
2013-03-06 |
2020-07-05 |
Janssen Pharmaceutica Nv |
مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
|
|
US8999992B2
(en)
|
2013-03-15 |
2015-04-07 |
Vm Pharma Llc |
Crystalline forms of tryosine kinase inhibitors and their salts
|
|
JP6634016B2
(ja)
*
|
2013-12-03 |
2020-01-22 |
アムジエン・インコーポレーテツド |
Ｎ−（４−（（３−（２−アミノ−４−ピリミジニル）−２−ピリジニル）オキシ）フェニル）−４−（４−メチル−２−チエニル）−１−フタラジンアミンの薬学的に許容される塩の結晶形態及びその使用
|
|
WO2016025561A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Forms and compositions of an erk inhibitor
|
|
US10301271B2
(en)
|
2014-09-17 |
2019-05-28 |
Purdue Pharma L.P. |
Crystalline forms of tyrosine kinase inhibitors and their salts
|
|
AU2016399168B2
(en)
*
|
2016-03-22 |
2021-01-21 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application
|